



Drug Coverage Policy

Effective Date8/1/2024
Coverage Policy Number.....IP0087
Policy Title.....Oriaahn

Gonadotropin-Releasing Hormone Antagonists – Oriaahn

- Oriaahn™ (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules – AbbVie)

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Each coverage request should be reviewed on its own merits. Medical directors are expected to exercise clinical judgment and have discretion in making individual coverage determinations. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

Cigna Healthcare Coverage Policy

OVERVIEW

Oriaahn, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist with added estrogen and progestin therapy, is indicated for the **management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women.**¹ Limitation of Use: Use should be limited to 24 months due to the risk of continued bone loss which may not be reversible.¹

Disease Overview

Uterine fibroids (leiomyomas) are benign tumors. They are the most frequent gynecologic benign disease.² Fibroids can be asymptomatic or cause symptoms; symptoms generally present as abnormal (heavy) uterine bleeding or pelvic pain/pressure. Heavy menstrual bleeding can cause associated problems, such as iron deficiency anemia. The actual prevalence of uterine fibroids is difficult to ascertain since many patients are asymptomatic, but it is estimated that fibroids can be detected in up to 80% of women by 50 years of age.³

Guidelines

Oriahnn is addressed in the American College of Obstetrician and Gynecologists guidelines on the management of symptomatic uterine leiomyomas (2021).⁴ Medical treatment options for uterine leiomyomas include agents that address only bleeding symptoms, such as GnRH antagonists, levonorgestrel-releasing intrauterine devices, contraceptive steroids, and tranexamic acid. Agents that reduce both bleeding and leiomyoma size include GnRH agonists and selective progesterone receptor modulators (SPRMs). SPRMs are not approved in the U.S. for the treatment of uterine leiomyomas. An oral GnRH antagonist, such as Oriahnn or Myfembree, can be considered for the treatment of abnormal uterine bleeding related to leiomyomas for up to 2 years. The hormonal add-back therapy is indicated to offset the hypoestrogenic effects of the product.

Medical Necessity Criteria

Oriahnn is considered medically necessary when the following criteria are met:

FDA-Approved Indication

1. Uterine Fibroids (Leiomyomas). Approve for up to 24 months if the patient meets ALL of the following (A, B, C, D, E, F, and G):

Note: Approve for **up to** 24 months. For example, a patient who has already received 6 months of treatment with Oriahnn should be approved for a duration of 18 months.

A) Patient is ≥ 18 years of age; AND

B) Patient is PREmenopausal (before menopause); AND

C) Patient is experiencing heavy menstrual bleeding associated with the uterine fibroids; AND

D) Uterine fibroids have been confirmed by a pelvic ultrasound, including transvaginal ultrasonography or sonohysterography; hysteroscopy; or magnetic resonance imaging; AND

E) Patient has tried at least one other therapy for the medical management of heavy menstrual bleeding; AND

Note: Examples of therapy for the medical management of heavy menstrual bleeding includes: combination estrogen-progestin contraceptives (oral tablets, vaginal ring, transdermal patch), levonorgestrel-releasing intrauterine systems [e.g., Mirena, Liletta], oral progesterone (e.g., medroxyprogesterone acetate), depo-medroxyprogesterone injection, tranexamic acid tablets.

F) Patient has **not** previously received a continuous regimen of 24 months or longer of therapy with Oriahnn or Myfembree; AND

G) The medication is prescribed by or in consultation with an obstetrician-gynecologist or a health care practitioner who specializes in the treatment of women's health.

When coverage is available and medically necessary, the dosage, frequency, duration of therapy, and site of care should be reasonable, clinically appropriate, and supported by evidence-based literature and adjusted based upon severity, alternative available treatments, and previous response to therapy.

Receipt of sample product does not satisfy any criteria requirements for coverage.

Conditions Not Covered

Any other use is considered experimental, investigational, or unproven, including the following (this list may not be all inclusive; criteria will be updated as new published data are available):

1. Heavy Menstrual Bleeding not associated with Uterine Fibroids.

Oriahnn has been shown to be effective in reducing heavy menstrual bleeding only in women with uterine fibroids.¹

References

1. Oriahnn™ co-packaged capsules [prescribing information]. North Chicago, IL: AbbVie; June 2023.
2. Neri M, Melis G, Giancane E, et al. Clinical utility of elagolix as an oral treatment for women with uterine fibroids: A short report on the emerging efficacy data. *Int J Womens Health*. 2019;11:535-546.
3. De La Cruz MS, Buchanan EM. Uterine Fibroids: Diagnosis and Treatment. *Am Fam Physician*. 2017;95(2):100-107.
4. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Management of Symptomatic Uterine Leiomyomas. No. 228. June 2021. Available at: <https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2021/06/management-of-symptomatic-uterine-leiomyomas>. Accessed on April 5, 2024.

Revision Details

Type of Revision	Summary of Changes	Date
Annual Revision	Updated coverage policy title from <i>Oriahnn</i> to <i>Gonadotropin-Releasing Hormone Antagonists - Oriahnn</i> . Updated initial approval authorization from 12 months to 24 months. Removed reauthorization criteria.	8/1/2024

The policy effective date is in force until updated or retired.

“Cigna Companies” refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2024 The Cigna Group.